Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 829-835

  Cha, Zhanshan ^a   Li, Chen ^b   Zang, Yan ^a   Gu, Haihui ^a   Guo, Huijun ^a   Li, Jinqi ^a   Fang, Yuan ^c   Petersen, Thomas F ^c   Li, Jing ^d   Karas, Richard O ^e   Hamilton, Michele L ^f   Qian, Baohua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c BGC Biotechnology Research Center   (China)

^d Department of Hematology   (China)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; BLDCL; Remission; Rituximab

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; IMMUNOGLOBULIN D; INFLUENZA VIRUS HEMAGGLUTININ; RITUXIMAB; TETANUS TOXIN; ANTINEOPLASTIC AGENT; CD19 MOLECULE, HUMAN; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; PLASMABLAST; PRIORITY JOURNAL; TUMOR REGRESSION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; REMISSION; YOUNG ADULT;

ADULT; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHENOTYPE; REMISSION INDUCTION; RITUXIMAB; YOUNG ADULT;

EID: 84938785392     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3872-6     Document Type: Article

References (24)

1. Horner MJ, Ries LAG, Krapcho M, Eisner MP, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1975–2006. [Internet]. Statistics (Ber). 2006. Available from: http://seer.cancer.gov/csr/1975_2002/
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.
3. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50.
4. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.
5. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.
6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.
7. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–86.
8. Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541–70.
9. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011;11:251–63.
10. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595–621.
11. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–63.
12. Allen CDC, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007;27(2):190–202.
13. Shaffer AL, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610.
14. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21.
15. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell. 2010;141(1):27–38.
16. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.
17. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9:235–45.
18. Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol. 2011;2:83.
19. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52.
20. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol. 2010;28:185–210.
21. Bour-jordan H, Bluestone JA. Commentaries B cell depletion: a novel therapy for autoimmune diabetes ? J Clin Invest. 2007;117:3642–5.
22. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol. 2011;29:273–93.
23. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67:134–40.
24. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102:1070–1.